Table 1.
Data are given as mean (SD)
| Controls (n = 17) | Typical AD (n = 21) | Atypical AD (n = 16) | |
|---|---|---|---|
| Age, y | 68.5 (3.9) | 68.9 (7) | 66.3 (7.2) |
| Sex (Male/female) | 5/12 | 10/11 | 6/10 |
| No. patients with CDR = 0 | 17 | 0 | 0 |
| No. patients with CDR = 0.5 | 0 | 15 | 12 |
| No. patients with CDR = 1 | 0 | 6 | 4 |
| MMSE | 28.8 (1.0) | 24.0 (3.5)** | 21.6 (2.2)* , ** |
| Episodic Memory Score 1 | 89.9 (6.5) | 40.8 (19.2) ** | NA |
| FCSRT free recall (max score:48) | 32.2 (5.8) | 10.1 (7.4) ** | NA |
| FCSRT total recall (max score 48) | 47.0 (1.3) | 24.2 (10.8) ** | NA |
| Doors A test (max score:12) | 10.2 (1.3) | 6.5 (2.5) ** | 6.7 (2.4)** |
| Cognitive Parietal Score 2 | 156.5 (1.5) | 147.8 (13.8) | 125.9 (22.8)* , ** |
| Denomination (max score: 80) | 79.6 (0.6) | 76.3 (4.2) | 71.9 (7.8)* , ** |
| Gestural praxis (max score: 36) | 35.5 (0.9) | 34.4 (2.3) | 27.2 (11.3)* , ** |
| ROCF copy (max score: 36) | 35.4 (0.9) | 31.1 (10.5) | 21.9 (15.2)** |
| Construction score of the MATTIS DRSγ (max score: 6) | 6.0 (0) | 5.9 (0.4) | 4.9 (1.7)* |
| Executive functions | |||
| Category fluency (2 minutes) | 34.4 (10.1) | 19.0 (5.6) ** | 14.6 (6.3)** |
| Forward digit span | 5.6 (1.2) | 5.3 (1.0) | 4.9 (1.2) |
| Backward digit span | 4.5 (1.1) | 4.3 (1.1) | 2.6 (0.9)* , ** |
| Similarities WAIS | 23.8 (3.6) | 19.8 (4.5)*** | 14.2 (4.8)* , ** |
| MADRS | 5.3 (3.5) | 5.5 (6.5) | 7.6 (5.3) |
| Treatment | |||
| AchEI, No./total No. (%) | 0/17 (0) | 16/21 (76) | 15/16 (94) |
| SSRIs, No./total No. (%) | 0/17 (0) | 9/21 (43) | 9/16 (56) |
| SSNIs, No./total No. (%) | 0/17 (0) | 4/21 (19) | 2/16 (12.5) |
| GCI [11C] –PIB | 1.30 (0.11) | 2.95 (0.67)** | 2.67 (0.62)** |
| CSF IATI Score | NA | 0.54 (0.21) | 0.45 (0.17) |
| LC‐I | 1.28 ± 0.04 | 1.23 ± 0.04** | |
| 1.24 ± 0.04** | 1.21 ± 0.03 ** | ||
| HV/TIV | 2.38 (0.18) | 2.05 (0.34) *** | 2.15 (0.22) |
| FAZEKAS Score | |||
| Score = 0/1/2 | 11/5/1 | 13/6/2 | 7/3/6 |
IATI score: Innotest Amyloid Tau Index (IATI) score was calculated using the formula: amyloid‐β42/[240 + (1.18xT‐tau)]).
AD, Alzheimer’s disease; CDR, Clinical Dementia Rating scale; MMSE, Mini‐Mental State examination; FCSRT, Free and Cued Selective Reminding Test, maximal score = 48, the FCSRT was not applicable (NA) in atypical AD patients due to aphasia; ROCF recall, Rey figure recall; MATTIS DRS, MATTIS Dementia Rating Scale; WAIS, Wechsler Adult Intelligence Scale; MADRS, Montgomery‐Asberg Depression Rating Scale; AChEI, acetylcholinesterase inhibitors; SSRIs, selective serotonin reuptake inhibitors; SSNIs, serotonin‐norepinephrine reuptake inhibitors; GCI, global cortical index; PiB‐PET imaging was acquired in 17 controls, 21 typical AD, and 13 atypical AD. HV/TIV, hippocampal volume normalized to the total intracranial volume.
The episodic memory score was defined by the sum of FCSRT free and total recall and Doors A test scores (maximal score = 102).
The cognitive parietal score was defined by the sum of denomination, gestural praxis, and visuo‐constructive (Rey and MATTIS figures copy) scores (maximal score = 156).
P < 0.05 between typical and atypical AD,
P ≤ 0.005 in patients versus controls,
P < 0.05 in patients versus controls.